阿德福韦酯联合拉米夫定治疗乙肝肝硬化的临床效果观察

Clinical effect observation of adefovir dipivoxil combined with lamivudine in the treatment of hepatitis B cirrhosis

目的:探讨阿德福韦酯及拉米夫定联用治疗乙肝肝硬化的有效性及安全性。方法:2010-2013年收治乙肝肝硬化患者70例,随机分成两组,每组35例,对照组实施阿德福韦酯治疗,观察组实施阿德福韦酯及拉米夫定联用,比较两组的临床治疗效果及药物安全性。结果:观察组治疗后的血清HBV-DNA水平要较其治疗前对照组更理想,差异有统计学意义(P<0.05);观察组治疗后的总胆红素和白蛋白均较对照组改善更明显,差异有统计学意义(P<0.05);两组治疗期间均未有患者出现严重不适。结论:阿德福韦酯及拉米夫定联用治疗乙肝肝硬化能有效改善患者的肝功能,而且安全性较高,值得临床推广及应用。

Objective:To explore the efficacy and safety of adefovir dipivoxil combined with lamivudine in the treatment of hepatitis B cirrhosis.Methods:70 patients with hepatitis B cirrhosis were divided into two groups random Ly from 2010 to 2013,each group with 35 cases.The control group were treated with adefovir dipivoxil and the observation group were treated with adefovir dipivoxil combined with lamivudine.Compare clinical curative effect and drug safety of two groups.Results:After treatment,the serum HBV- DNA level of the observation group was more ideal than before the treatment,or than that of the control group;the difference was statistically significant(P<0.05).Total bilirubin and albumin of the observation group improved more obviously than that of the control group after treatment;the difference was statistically significant(P<0.05).There were no patients with severe discomfort in two groups during treatment.Conclusion:Adefovir dipivoxil combined with lamivudine in the treatment of hepatitis B cirrhosis can improve liver function effectively and had high security,worthy of clinical popularization and application.